natgillin/translations-raw huggingface dataset:
They were either derived from spontaneous post-marketing reports and frequency cannot be determined, or they were derived from risperidone (any formulation) or oral paliperidone clinical trials data and/or post-marketing reports. 
Izhajajo iz spontanih poročil v obdobju po prihodu zdravila na trg in njihove pogostnosti ni mogoče določiti, ali iz podatkov kliničnih preskušanj in/ali poročil v obdobju po prihodu zdravila na trg z risperidonom (katera koli oblika) ali paliperidonom v peroralni obliki.
In a study with oral paliperidone in subjects with moderate hepatic impairment (Child-Pugh class B), the plasma concentrations of free paliperidone were similar to those of healthy subjects. 
V študiji peroralnega paliperidona pri preiskovancih z zmerno okvaro jeter (razred B po Child-Pughovi lestvici) so bile koncentracije prostega paliperidona v plazmi podobne kot pri zdravih preiskovancih.
The efficacy of TREVICTA in the maintenance treatment of schizophrenia in subjects who have been adequately treated for at least four months with 1-monthly paliperidone palmitate injectable and the last two doses of the same dosage strength was evaluated in one long-term randomised withdrawal double-blind, placebo-controlled study and one long-term double-blind, active-controlled, non-inferiority study. 
Učinkovitost zdravila TREVICTA za vzdrževalno zdravljenje shizofrenije pri bolnikih, ki so bili najmanj štiri mesece ustrezno zdravljeni z 1-mesečnimi injekcijami paliperidonijevega palmitata (in sta bila zadnja dva odmerka iste jakosti), so ocenjevali v eni dolgotrajni, randomizirani, dvojno slepi, s placebom nadzorovani študiji odtegnitve zdravila in drugi, dolgotrajni, dvojno slepi, aktivno nadzorovani študiji za oceno neinferiornosti zdravila.
Effect of smoking on the pharmacokinetics of paliperidone was not studied with TREVICTA. 
Vpliva kajenja na farmakokinetiko paliperidona pri uporabi zdravila TREVICTA niso preučevali.
Subjects who were considered clinically stable at the end of the 12-week stabilisation phase were then randomised 1:1 to TREVICTA or placebo in a variable duration double-blind phase (the dose of TREVICTA was the same as the last dose received during the stabilisation phase; this dose remained fixed throughout the double-blind phase). 
Bolnike, ki so jih po koncu 12-tedenske faze stabilizacije ocenili kot klinično stabilne, so nato randomizirali v razmerju 1:1 na prejemanje zdravila TREVICTA ali placeba v obdobju dvojno slepega zdravljenja z različnim trajanjem (odmerek zdravila TREVICTA je bil enak zadnjemu prejetemu odmerku v fazi stabilizacije in se ni spremenil celotno obdobje dvojno slepega zdravljenja).
Switching from TREVICTA to other antipsychotic medicinal products If TREVICTA is discontinued, its prolonged release characteristics must be considered. 
Prehod z zdravila TREVICTA na drugo antipsihotično zdravilo Ob ukinitvi zdravila TREVICTA je treba upoštevati njegovo podaljšano delovanje.
• sensation of spinning (vertigo), ringing in the ears, ear pain 
• vrtoglavica (občutek vrtenja), zvonjenje v ušesih, bolečina v ušesu
Medicinal products with dopamine receptor antagonistic properties have been associated with the induction of tardive dyskinesia characterised by rhythmical, involuntary movements, predominantly of the tongue and/or face. 
Zdravila z antagonističnim delovanjem na dopaminske receptorje so povezana z razvojem tardivne diskinezije, za katero so značilni ritmični, nehoteni gibi, predvsem jezika in/ali obraza.
Dispose properly 
Pripomočke pravilno zavrzite
Total clearance of paliperidone was reduced in subjects with impaired renal function by 32% on average in mild (CrCl = 50 to < 80 mL/min), 64% in moderate (CrCl = 30 to < 50 mL/min), and 71% in severe (CrCl = 10 to < 30 mL/min) renal impairment, corresponding to an average increase in exposure (AUCinf) of 1.5, 2.6, and 4.8-fold, respectively, compared to healthy subjects. 
Celokupni očistek paliperidona se je pri preiskovancih z okvaro ledvic v povprečju zmanjšal za 32% pri blagi okvari ledvic (CrCl = 50 do < 80 ml/min), za 64% pri zmerni (CrCL = 30 do < 50 ml/min) in za 71% pri hudi (CrCl = 10 do < 30 ml/min) okvari ledvic, kar je skladno s povprečnim povečanjem izpostavitve (AUCinf) za 1,5-, 2,6- oziroma 4,8-krat v primerjavi z zdravimi preiskovanci.
Patients with severe neutropenia (absolute neutrophil count 
Pri bolnikih s hudo nevtropenijo (absolutno število nevtrofilcev < 1 x 10
Based on the final analysis (N = 305), 42 subjects (29.0%) in the placebo group and 14 subjects (8.8%) in the TREVICTA group had experienced a relapse event during the double blind phase. 
Na osnovi končne analize (N = 305), je do relapsa med dvojno slepo fazo študije prišlo pri 42 preiskovancih (29,0%) v skupini, ki je prejemala placebo in pri 14 preiskovancih (8,8%) v skupini, ki je prejemala zdravilo TREVICTA.
How to use TREVICTA 
Kako uporabljati zdravilo TREVICTA
Missed doses If scheduled dose is missed and the time since last injection is 
Izpuščeni odmerki Izpuščeni odmerek in čas, ki je pretekel od zadnje injekcije
To avoid a missed dose of TREVICTA patients may be given the injection up to 2 weeks before or after the 3-month time point. 
Da preprečite spuščanje odmerka zdravila TREVICTA, lahko bolnikom zdravilo injicirate do 2 tedna pred 3-mesečnim časovnim rokom ali do 2 tedna po njem.
This interaction has not been studied with TREVICTA. 
Te interakcije z zdravilom TREVICTA niso preučevali.
TREVICTA, a 3-monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1-monthly paliperidone palmitate injectable product (see section 5.1). 
Zdravilo TREVICTA, 3-mesečna injekcija, je indicirano za vzdrževalno zdravljenje shizofrenije pri odraslih bolnikih, ki so klinično stabilni in so pred tem prejemali 1-mesečne injekcije paliperidonijevega palmitata (glejte poglavje 5.1).
Repeat-dose toxicity studies of intramuscularly injected paliperidone palmitate (the 1-monthly formulation) and orally administered paliperidone in rat and dog showed mainly pharmacological effects, such as sedation and prolactin-mediated effects on mammary glands and genitals. 
Študije toksičnosti z večkratnimi odmerki intramuskularno injiciranega paliperidonijevega palmitata (v obliki 1-mesečnih injekcij) in peroralnega paliperidona na podganah in psih so večinoma pokazale farmakološke učinke, kot so sedacija ter učinki prolaktina na mlečne žleze in spolovila.
• tardive dyskinesia (twitching or jerking movements that you cannot control in your face, tongue, 
• tardivna diskinezija (nenadzorovano trzanje in sunkoviti gibi, ki jih ne morete nadzorovati, na obrazu, jeziku ali drugih delih telesa).
Potential for other medicines to affect TREVICTA 
Možnost, da bodo druga zdravila vplivala na zdravilo TREVICTA
• a reaction at the injection site, including itching, pain or swelling. 
• reakcija ne mestu injiciranja, vključno s srbenjem, bolečino ali otekanjem.
Concomitant use of TREVICTA with risperidone or oral paliperidone 
Sočasna uporaba zdravila TREVICTA in risperidona ali peroralnega paliperidona
Due to the long-acting nature of TREVICTA, the patient's response to an adjusted dose may not be apparent for several months (see section 5.2). 
Zaradi podaljšanega sproščanja zdravila TREVICTA je bolnikov odziv na spremenjeno odmerjanje lahko opazen šele po več mesecih (glejte poglavje 5.2).
Hold the syringe upright and tap gently to make any air bubbles rise to the top. 
Injekcijsko brizgo postavite v pokončen položaj in jo nežno krcnite, da se morebitni zračni mehurčki dvignejo na vrh.
TREVICTA is intended for intramuscular use only. 
Zdravilo TREVICTA je namenjeno samo intramuskularni uporabi.
TREVICTA should not be used while breast-feeding. 
Zdravila TREVICTA se med dojenjem ne sme uporabljati.
The injection should be administered as soon as possible and then resume the 3-monthly injection schedule. 
Injekcijo je treba bolniku dati čim prej, nato pa nadaljevati z odmerjanjem na 3 mesece.
Male rats showed a statistically significant increase in mammary gland adenomas and carcinomas at 30 and 60 mg/kg/month which is 0.6 and 1.2 times the exposure level at the maximum recommended human 525 mg dose. 
Pri podganjih samcih so ugotovili statistično značilno povečanje pojavnosti adenomov in karcinomov mlečnih žlez, in sicer pri odmerkih 30 in 60 mg/kg/mesec, kar ustreza 0,6-oziroma 1,2-kratni izpostavljenosti največjemu priporočenemu odmerku pri človeku (525 mg).
Subjects received TREVICTA once every 3 months and received placebo-injectable medication for the other months to maintain the blind. 
Preiskovanci, ki so prejemali zdravilo TREVICTA enkrat na 3 mesece, so v preostalih mesecih prejemali injekcije s placebom, tako da je zdravljenje ostalo slepo.
Given the primary central nervous system (CNS) effects of paliperidone (see section 4.8), TREVICTA should be used with caution in combination with other centrally acting medicinal products, e.g., anxiolytics, most antipsychotics, hypnotics, opiates, etc. or alcohol. 
Ker paliperidon primarno deluje na osrednje živčevje (glejte poglavje 4.8), je treba zdravilo TREVICTA uporabljati previdno v kombinaciji z drugimi zdravili, ki tudi delujejo na osrednje živčevje, kot so anksiolitiki, večina antipsihotikov, uspavala, opiati in podobno, ali z alkoholom.
TREVICTA has not been studied in patients with renal impairment (see section 5.2). 
Zdravila TREVICTA niso preučevali pri bolnikih z okvaro ledvic (glejte poglavje 5.2).
Slowly and carefully press plunger rod upward to remove air. 
Počasi in previdno potisnite bat navzgor, da iztisnete zrak.
To avoid incomplete administration of TREVICTA, the pre-filled syringe must be shaken vigorously for at least 15 seconds within 5 minutes prior to administration to ensure a homogeneous suspension (see Information intended for medical or health care professionals). 
Da bo odmerek zdravila TREVICTA injiciran v celoti, je treba napolnjeno injekcijsko brizgo 5 minut pred odmerjanjem najmanj 15 sekund močno stresati, da postane suspenzija homogena (glejte Informacije za zdravnike in drugo zdravstveno osebje).
In animals treated with paliperidone palmitate an inflammatory reaction was seen at the intramuscular injection site. 
Pri živalih, ki so jim aplicirali paliperidonijev palmitat, so opazili vnetno reakcijo na mestu intramuskularnega injiciranja.
Although TREVICTA was not studied in patients with hepatic impairment, no dose adjustment is required in patients with mild or moderate hepatic impairment. 
Čeprav zdravila TREVICTA niso preučevali pri bolnikih z okvaro jeter, pri bolnikih z blago ali zmerno okvaro jeter ni treba prilagajati odmerka.
Paliperidone is excreted in the breast milk to such an extent that effects on the breast-fed infant are likely if therapeutic doses are administered to breast-feeding women. 
Paliperidon se izloča v materino mleko v tolikšni meri, da bi verjetno vplival na dojenega otroka, če bi doječa mati prejemala terapevtske odmerke zdravila.
Hypersensitivity reactions can occur even in patients who have previously tolerated oral risperidone or oral paliperidone (see section 4.8). 
Preobčutljivostne reakcije se lahko pojavijo tudi pri bolnikih, ki so dobro prenašali peroralni risperidon ali peroralni paliperidon (glejte poglavje 4.8).
Following intramuscular injection of TREVICTA at doses of 175-525 mg in the deltoid muscle, on average, an 11-12% higher Cmax was observed compared with injection in the gluteal muscle. 
Po intramuskularnem injiciranju zdravila TREVICTA v odmerkih 175-525 mg v deltoidno mišico so opazili v povprečju za 11-12% višjo Cmax kot pri injiciranju v glutealno mišico.
The combined use of psychostimulants (e.g. methylphenidate) with paliperidone can lead to extrapyramidal symptoms upon change of either or both treatments (see section 4.4). 
Kombinirana uporaba psihostimulansov (metilfenidata) in paliperidona lahko ob spremembi enega ali obeh zdravil povzroči ekstrapiramidne simptome (glejte poglavje 4.4).
Figure 2: Kaplan-Meier plot of time to relapse comparing TREVICTA and 1-monthly paliperidone palmitate injectable 
Slika 2: Kaplan-Meierjeva krivulja časa do relapsa primerjave zdravila TREVICTA in 1-mesečnih injekcij paliperidonijevega palmitata
• irritability, depression, anxiety 
• razdražljivost, depresija, tesnoba
In oral carcinogenicity studies of risperidone in rats and mice, increases in pituitary gland adenomas (mouse), endocrine pancreas adenomas (rat), and mammary gland adenomas (both species) were seen. 
V študijah kancerogenosti peroralnega risperidona na podganah in miših so opazili povečano pogostnost adenomov hipofize (pri miših), adenomov endokrinega dela trebušne slinavke (pri podganah) in adenomov mlečnih žlez (pri obeh vrstah).
It is important to only use the needles provided in the TREVICTA pack. 
Pomembno je, da uporabljate samo injekcijske igle, ki so priložene pakiranju zdravila TREVICTA.
• an increase of CPK (creatine phosphokinase) in your blood, an enzyme which is sometimes released with muscle breakdown 
• povišana koncentracija kreatin fosfokinaze (CPK) v krvi (encima, ki se včasih sprosti ob razpadanju mišic)
Long-acting 3-monthly paliperidone palmitate injection versus other paliperidone formulations 
Dolgodelujoče 3-mesečne injekcije paliperidonijevega palmitata v primerjavi z drugimi formulacijami paliperidona
• increased GGT (a liver enzyme called gamma-glutamyltransferase) in your blood, increased liver enzymes in your blood 
• povišana koncentracija GGT (jetrnega encima, ki ga imenujemo gama-glutamil transferaza) v krvi, povišana koncentracija jetrnih encimov v krvi
The disposition of a single oral dose of a paliperidone 3 mg prolonged release tablet was studied in subjects with varying degrees of renal function. 
Izločanje enkratnega 3 mg odmerka paliperidona v obliki tablet s podaljšanim sproščanjem so preučevali pri preiskovancih z različnimi stopnjami delovanja ledvic.
Then administer TREVICTA (into deltoid a or gluteal muscle) 
Nadaljujte z odmerjanjem zdravila TREVICTA (v deltoidno a ali glutealno mišico)
• experience fever, muscle stiffness, sweating or a lowered level of consciousness (a disorder called “Neuroleptic Malignant Syndrome”). 
• imate povišano telesno temperaturo, okorele mišice, se potite ali imate zmanjšano stopnjo zavesti (stanje, ki se imenuje nevroleptični maligni sindrom).
logrank test, p-value<0.0001 
Ocenjen odstotek bolnikov brez relapsa test log rank, vrednost p<0,0001
Caution should be exercised when paliperidone is prescribed in patients with known cardiovascular disease or family history of QT prolongation, and in concomitant use with other medicinal products thought to prolong the QT interval. 
Pri predpisovanju paliperidona bolnikom z znano srčnožilno boleznijo ali s podaljšanjem intervala QT v družinski anamnezi ter pri sočasni uporabi paliperidona z drugimi zdravili, ki tudi podaljšajo interval QT, je potrebna previdnost.
In rat reproduction studies with oral risperidone, which is extensively converted to paliperidone in rats and humans, adverse effects were seen on the birth weight and survival of the offspring. 
V študijah reprodukcije pri podganah z uporabo peroralnega risperidona, ki se tako pri podganah kot pri človeku v velikem obsegu pretvarja v paliperidon, so opažali neželene učinke v smislu zmanjšanja porodne teže in preživetja mladičev.
The following table provides recommended dose conversion regimens to allow patients previously stabilised on different doses of TREVICTA to attain similar paliperidone exposure with paliperidone prolonged release tablets. 
V preglednici so navedene priporočene sheme odmerjanja, s katerimi lahko bolniki, ki so bili stabilizirani z različnimi odmerki zdravila TREVICTA, dosežejo podobno izpostavljenost paliperidonu tudi s tabletami paliperidona s podaljšanim sproščanjem.
• are aware of having dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood. 
• veste, da imate nevarno majhno število določenih tipov belih krvnih celic, ki jih potrebujete za obrambo pred okužbo v krvi.
Action 
Ukrep
You will receive an injection of TREVICTA in the upper arm or buttocks once every 3 months. 
Zdravilo TREVICTA vam bodo injicirali v nadlaket ali zadnjico enkrat na 3 mesece.
As elderly patients may have reduced renal function, see Renal impairment below for dosing recommendations in patients with renal impairment. 
Ker imajo lahko starejši bolniki oslabljeno delovanje ledvic, za priporočeno odmerjanje pri bolnikih z okvaro ledvic glejte odstavek Okvara ledvic spodaj.
Due to its extremely low water solubility, the 3-monthly formulation of paliperidone palmitate dissolves slowly after intramuscular injection before being hydrolysed to paliperidone and absorbed into the systemic circulation. 
Zaradi izjemno majhne topnosti v vodi se paliperidonijev palmitat po intramuskularnem injiciranju 3-mesečne formulacije počasi raztaplja, nato pride do hidrolize v paliperidon in absorpcije v sistemski krvni obtok.
A total of 379 subjects then received a single dose of TREVICTA in either the deltoid or gluteal muscle in the open-label stabilisation phase (dose was a 3.5 multiple of the last dose of 1-monthly paliperidone palmitate). 
Nato je skupno 379 preiskovancev med odprtim delom zdravljenja v fazi stabilizacije prejelo enkraten odmerek zdravila TREVICTA bodisi v deltoidno ali glutealno mišico (odmerek zdravila TREVICTA je bil 3,5-kratnik zadnjega odmerka 1-mesečnega paliperidonijevega palmitata).
Patients with a history of a clinically significant low white blood cell count (WBC) or a drug-induced leucopenia/neutropenia should be monitored during the first few months of therapy and discontinuation of TREVICTA should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors. 
Bolnike, ki so že imeli klinično pomembno majhno število levkocitov ali z zdravilom izzvano levkopenijo/nevtropenijo, je treba v prvih mesecih zdravljenja spremljati in ob pojavu prvih znakov klinično pomembnega zmanjšanja števila levkocitov in odsotnosti drugih vzročnih dejavnikov, razmisliti o prekinitvi zdravljenja z zdravilom TREVICTA.
Dominating central serotonin antagonism may reduce the tendency of paliperidone to cause extrapyramidal side effects. 
Dominantno antagonistično delovanje na serotonergične receptorje v osrednjem živčevju lahko zmanjša nagnjenost paliperidona k povzročanju ekstrapiramidnih neželenih učinkov.
TREVICTA can then be resumed after the patient has been adequately treated with 1-monthly paliperidone palmitate injectable preferably for four months or more. 
Zdravilo TREVICTA je nato mogoče ponovno uvesti po tem, ko je bil bolnik ustrezno zdravljen z 1-mesečnimi injekcijami paliperidonijevega palmitata, najbolje štiri mesece ali več.
For subjects that met randomisation criteria at weeks 14 and 17, 1,016 were randomised in a 1:1 ratio to continue on monthly injections of 1-monthly paliperidone palmitate injectable or to switch to TREVICTA with a 3.5 multiple of the week 9 and 13 dose of 1-monthly paliperidone palmitate injectable for 48 weeks. 
Izmed bolnikov, ki so v 14. in 17. tednu ustrezali merilom za randomizacijo, so jih 1.016 v razmerju 1:1 randomizirali tako, da so 48 tednov bodisi nadaljevali z 1-mesečnimi injekcijami paliperidonijevega palmitata ali pa so prešli na zdravilo TREVICTA z odmerkom, ki je bil 3,5-kratnik odmerka 1-mesečne injekcije paliperidonijevega palmitata v 9. in 13. tednu.
A minor decrease in the amount of active substance excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration. 
Majhno zmanjšanje količine učinkovine, ki se izloči nespremenjena z urinom, kaže, da ima sočasno jemanje s karbamazepinom majhen učinek na metabolizem, ki poteka s CYP, ali biološko uporabnost paliperidona.
Needles from the 1-monthly paliperidone palmitate injectable pack or other commercially available needles must not be used when administering TREVICTA (see Information intended for medical or health care professionals). 
Igle, ki so priložene pakiranju z 1-mesečnimi injekcijami paliperidonijevega palmitata in druge na trgu dostopne igle, niso primerne in se jih ne sme uporabljati za injiciranje zdravila TREVICTA (glejte Informacije za zdravnike in drugo zdravstveno osebje).
Pre-filled syringe (cyclic-olefin-copolymer) with a plunger stopper, backstop, and tip cap (bromobutyl rubber) with a thin wall 22G 1½ inch (0.72 mm x 38.1 mm) safety needle and a thin wall 22G 1 inch (0.72 mm x 25.4 mm) safety needle. 
Napolnjena injekcijska brizga (kopolimer cikloolefina) z batom, varovalom in vrhnjo zaporko (iz bromobutilne gume) ter varnostna igla s tanko steno velikosti 0,72 mm x 38,1 mm (dolžine 1½ palca in velikosti 22G) in varnostna igla s tanko steno velikosti 0,72 mm x 25,4 mm (1 palec, velikost 22G).
As diabetes mellitus or worsening of pre-existing diabetes mellitus have been seen with patients taking this medicine, your doctor should check for signs of high blood sugar. 
Med jemanjem tega zdravila so pri bolnikih opazili sladkorno bolezen ali njeno poslabšanje, zato bo zdravnik preverjal, če imate znake povečane koncentracije sladkorja v krvi.
The total exposure of paliperidone following TREVICTA administration was dose-proportional over a 175-525 mg dose range, and approximately dose-proportional for Cmax. 
Celokupna izpostavljenost paliperidonu po injiciranju zdravila TREVICTA je sorazmerna z velikostjo odmerka v okviru odmerjanja 175-525 mg, Cmax pa je približno sorazmerna z velikostjo odmerka.
Administer 1-monthly paliperidone palmitate injectable, two doses one week apart (into deltoid muscle) 
Injicirajte 1-mesečni injekciji paliperidonijevega palmitata: dva odmerka s presledkom enega tedna (v deltoidno mišico)
Do not remove the pouch until the syringe and needle are securely attached. 
Zaščitnega omota ne odstranjujte, dokler ni injekcijska igla trdno nameščena na injekcijsko brizgo.
Paliperidone may induce orthostatic hypotension in some patients based on its alpha-adrenergic blocking activity. 
Paliperidon lahko pri nekaterih bolnikih povzroči ortostatsko hipotenzijo, ker zavira adrenergične receptorje alfa.
In the clinical trials of TREVICTA, akathisia, dyskinesia, dystonia, parkinsonism, and tremor were reported in 3.9%, 0.8%, 0.9%, 3.6%, and 1.4% of subjects, respectively. 
V kliničnih preskušanjih zdravila TREVICTA so o akatiziji poročali pri 3,9% preiskovancev, o diskineziji pri 0,8%, o distoniji pri 0,9%, o parkinsonizmu pri 3,6% in o tremorju pri 1,4% preiskovancev.
90 kg or more yellow hub 
90 kg ali več rumeni nastavek 22G x 1 ½ palca
Switching from other antipsychotic medicinal products Patients should not be switched directly from other antipsychotics as 3-monthly paliperidone palmitate injectable should only be initiated after the patient is stabilised on the 1-monthly paliperidone palmitate injectable. 
Bolniki ne smejo preiti direktno z drugih antipsihotičnih zdravil, ker se lahko 3-mesečne injekcije paliperidonijevega palmitata uvede šele potem, ko je bolnik stabilen na 1-mesečnih injekcijah paliperidonijevega palmitata.
• dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood 
• nevarno majhno število določenih vrst belih krvnih celic, ki jih potrebujete v krvi za obrambo pred okužbo
It should be injected slowly, deep into the deltoid or gluteal muscle. 
Zdravilo je treba injicirati počasi, globoko v deltoidno ali glutaelno mišico.
Caution is warranted in patients receiving both, psychostimulants (e.g., methylphenidate) and paliperidone concomitantly, as extrapyramidal symptoms could emerge when adjusting one or both medicinal products. 
Pri bolnikih, ki sočasno prejemajo psihostimulanse (metilfenidat) in paliperidon je potrebna previdnost, ker se ob prilagajanju enega ali obeh zdravil lahko pojavijo ekstrapiramidni simptomi.